
Boehringer Ingelheim and ZEISS Partner to Prevent Vision Loss; Partnership Aims to Create AI Tools and Early Predictive Markers for Eye Disease
Boehringer Ingelheim and ZEISS Medical Technology, have announced a new collaboration aimed at developing predictive analytics for early detection of eye diseases. This partnership aims to tackle the global issue of vision loss caused by serious eye diseases by leveraging advanced technology and data analytics.
Over 300 million people worldwide are currently at risk of losing their eyesight due to conditions that lead to retinal dysfunction. With an aging global population and increasing health disparities, the number of individuals experiencing vision loss is projected to rise. Undiagnosed and untreated retinal diseases can have devastating consequences, impacting people’s independence, mental health, and overall quality of life.
The primary goal of this strategic collaboration is to identify early-stage markers of retinal diseases using ZEISS Medical Technology’s cloud-connected devices and AI-assisted analysis of extensive image datasets. By doing so, the partnership aims to facilitate the development of personalized and precise treatments for chronic retinal diseases in their early stages.
Euan S. Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology, emphasized the importance of collaboration in driving innovation, particularly in the context of combating vision loss.